Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study

Cancer

Volumn 121, Issue 14, 2015, Pages 2411-2421

  Pasqualini, Renata ^a,c   Millikan, Randall E ^a   Christianson, Dawn R ^a,b   Cardõ Vila, Marina ^a,c   Diessen, Wouter H P ^a,d   Giordano, Ricardo J ^a,e   Hajitou, Amin ^a,f   Hoang, Anh G ^a   Wen, Sijin ^a,g   Barnhart, Kirstin F ^a,h   Baze, Wallace B ^a   Marcott, Valerie D ^a   Hawke, David H ^a   Do, Kim Anh ^a   Navone, Nora M ^a   Efstathiou, Eleni ^a   Troncoso, Patricia ^a   Lobb, Roy R ^b   Logothetis, Christopher J ^a   Arap, Wadih ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b Arrowhead Research Corporation   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d ITHERA MEDICAL GMBH   (Germany)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g WEST VIRGINIA UNIVERSITY   (United States)

^h ABBOTT LABORATORIES   (United States)

Author keywords

bone metastasis targeting peptidomimetic 11; clinical trial; interleukin 11 receptor ; prostate cancer; vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; BONE METASTASIS-TARGETING PEPTIDOMIMETIC-11; IL11RA PROTEIN, HUMAN; INTERLEUKIN 11 RECEPTOR ALPHA; PEPTIDE;

AGED; BONE NEOPLASMS; CASTRATION RESISTANT PROSTATE CANCER; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; HUMAN; KIDNEY; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEINURIA; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERLEUKIN-11 RECEPTOR ALPHA SUBUNIT; KIDNEY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PEPTIDES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEINURIA; TREATMENT OUTCOME;

EID: 84934437161     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29344     Document Type: Article

References (30)

1. Pasqualini R, Moeller BJ, Arap W,. Leveraging molecular heterogeneity of the vascular endothelium for targeted drug delivery and imaging. Semin Thromb Hemost. 2010; 36: 343-351.
2. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W,. Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev. 2006; 58: 1622-1654.
3. Ozawa MG, Zurita AJ, Dias-Neto E, et al., Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends Cardiovasc Med. 2008; 18: 126-132.
4. Arap W, Kolonin MG, Trepel M, et al., Steps toward mapping the human vasculature by phage display. Nat Med. 2002; 8: 121-127.
5. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W,. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep. 2003; 33: 20-26.
6. Pentz RD, Cohen CB, Wicclair M, et al., Ethics guidelines for research with the recently dead. Nat Med. 2005; 11: 1145-1149.
7. Staquicini FI, Cardõ-Vila M, Kolonin MG, et al., Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011; 108: 18637-18642.
8. Zurita AJ, Troncoso P, Cardõ-Vila M, Logothetis CJ, Pasqualini R, Arap W,. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res. 2004; 64: 435-439.
9. Cardõ-Vila M, Zurita AJ, Giordano RJ, et al., A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11 [serial online]. PLoS One. 2008; 3: e3452.
10. Gu C, Liu L, He Y, Jiang J, Yang Z, Wu Q,. The binding characteristics of a cyclic nonapeptide, c(CGRRAGGSC), in LNCaP human prostate cancer cells. Oncol Lett. 2012; 4: 443-449.
11. Wang W, Ke S, Kwon S, et al., A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem. 2007; 18: 397-402.
12. Ellerby HM, Arap W, Ellerby LM, et al., Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999; 5: 1032-1038.
13. Arap W, Haedicke W, Bernasconi M, et al., Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA. 2002; 99: 1527-1531.
14. Arap MA, Lahdenranta J, Mintz PJ, et al., Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell. 2004; 6: 275-284.
15. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W,. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004; 10: 625-632.
16. Lewis VO, Ozawa MG, Deavers MT, et al., The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res. 2009; 69: 1995-1999.
17. Barnhart KF, Christianson DR, Hanley PW, et al., A peptidomimetic targeting fat causes weight loss and improved insulin resistance in obese monkeys [serial online]. Sci Transl Med. 2011; 3: 108ra112.
18. Li ZG, Mathew P, Yang J, et al., Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. J Clin Invest. 2008; 118: 2697-2710.
19. US Food and Drug Administration. Guidance for Industry Safety Testing of Drug Metabolites. Available at: http://www.fda.gov/SiteIndex/default.htm. Accessed February 26, 2015.
20. US Food and Drug Administration. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Available at: http://www.fda.gov/SiteIndex/default.htm. Accessed February 26, 2015.
21. Cancer Therapy Evaluation Program, National Cancer Institute. Protocol Development: CTCAE v4.0 Open Comment Period. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm#ctc-30. Accessed February 26, 2015.
22. Scher HI, Halabi S, Tannock I, et al., Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
23. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al., Phase I study of Samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009; 27: 2436-2442.
24. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ,. Phase I study of concurrent weekly docetaxel and repeated Samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009; 27: 3319-3324.
25. Tran C, Ouk S, Clegg NJ, et al., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324: 787-790.
26. Scher HI, Fizazi K, Saad F, et al., Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-1197.
27. de Bono JS, Logothetis CJ, Molina A, et al., Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
28. Reid AH, Attard G, Danila DC, et al., Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010; 28: 1489-1495.
29. Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB,. Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol. 2012; 9: 376-385.
30. de Bono JS, Oudard S, Ozguroglu M, et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-1154.